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Patients with a single ventricle congenital heart defect are prone to increased 
volume loading, which can lead to heart failure and require mechanical circulatory 
support.  A ventricular assist device (VAD) can serve as a bridge treatment option for 
these patients.  However, in VAD support cases, pediatric patients possessing congenital 
heart defects have lower survival rates than patients without and outcomes worsen further 
in single ventricle cases.  Performance differences between pulsatile and continuous flow 
VADs have also been clinically observed, but the underlying mechanism remains poorly 
understood. 
Six pediatric, stage 1 single ventricle patients (cohort mean BSA = 0.30 m2) were 
considered.  The cardiovascular system was computationally simulated using a lumped-
parameter network (LPN) tuned to patient specific data.  A first set of simulations 
emulated current clinical implementation of VADs in single ventricle patients.  A second 
set modified VAD settings with the goal to further improve cardiac output (CO). 
For all patients, optimal CO was at least 1 L min-1 greater with the continuous 
flow VAD compared that of pulsatile flow (p=0.0009).  The 25 and 50 mL pulsatile flow 
VADs exhibited incomplete filling at higher heart rates that reduced CO as much as 0.26 
and 1.4 L min-1 (9.7% and 37.3%) below design expectations respectively.  Optimization 
of pulsatile flow VAD settings to improve filling did not achieve statistically significant 
(p<0.05) improvement.  Results corroborate anecdotal clinical experience associating 
continuous flow VADs with superior CO and ventricular unloading in single ventricle 
 iii 
patients.  Future work should aim to improve models for ventricular suction resistance 
and the passive pressure-volume relationship at negative ventricular pressures. 
As part of future work, the single ventricle LPN was modified to simulate resting 
and exercise physiologies of example adult patients with normal bi-ventricular 
circulations.  Correlations with exercise level for key physiological parameters were 
developed using prior literature data.  Considerations for patient fitness level and age 
were also incorporated as appropriate.  This model produced resting physiology within 
tolerance of prior literature data and exercise physiologies for two example patients 
within 10% of prior data for CO and mean arterial pressure.  This modified LPN serves 
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Children born with a single ventricle congenital heart defect require staged 
surgical intervention to enable survival.  The first of three stages typically involves 
insertion of a systemic-to-pulmonary shunt, either in isolation or as part of a Norwood 
procedure.  This shunt provides the infant’s only source of pulmonary blood flow.  
However, patients remain at risk of heart failure (HF) due to increased volume loading on 
the single working ventricle (1–3).  A ventricular assist device (VAD) can be used as a 
mechanical bridge-to-recovery or bridge-to-transplant support option for these patients.  
VADs have been used in the single ventricle circulation (4–10) and normal circulation 
(11–17), but survival rates for pediatric patients with congenital heart defects remain 
approximately 25% lower than those without (18) and outcomes worsen further in single 
ventricle cases.  Therefore, increased knowledge of mechanisms affecting VAD 
performance in single ventricle circulations is needed to improve clinical outcomes for 
these patients. 
VADs can generally be categorized as either pulsatile flow or continuous (i.e. 
steady) flow.  Pulsatile flow VADs are the first generation design that emulate the heart’s 
distinct phases of diastole (filling) and systole (ejection).  The Berlin Heart EXCOR 
VAD remains the only such FDA approved device for infants.  Blood flow in and out of 
the VAD is driven via a membrane, and valves are located at the inlet and outlet of this 
“ventricle.”   The membrane motion is controlled by an air chamber connected to a 
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pneumatic, external air compressor.  By contrast, continuous flow VADs have pump 
rotors that produce a pressure rise for a particular flowrate and rotational speed.  Second 
generation axial designs and third generation centrifugal designs use rotors supported by 
bearings (19, 20).  Continuous flow designs generally have better reliability and smaller 
size while reducing risk of infection, bleeding, trauma, and thrombus formation (21–29).  
While continuous flow devices are now used almost exclusively in adults and older 
children, none are specifically designed for long-term use in infants.  Successful bridge 
treatment of pediatric patients with continuous flow VADs has been demonstrated (30), 
however further experience is needed in single ventricle circulations.  Studies have 
suggested that pulsatile flow VADs may promote better ventricular unloading and more 
natural physiology (21, 22, 24–26), however continuous flow VADs may encourage 
faster recovery of myocardial tissue due to less pulsatile trauma on the heart tissue (27, 
31). 
Computational simulations of the cardiovascular system can be used to model the 
interaction of VADs and other devices with the circulatory physiology and predict 
hemodynamic results.  Lumped-parameter networks (LPN) and state space models offer a 
reduced-order modeling approach to simulate the entire cardiovascular system at a 
relatively low computational cost.  These use a zero dimensional approach by making an 
analogy to electrical circuits and forming a system of ordinary differential equations 
solved by numerical integration (32–42).  In this study, a LPN model is used to assess 
VAD performance in the patient cohort.  Three dimensional computational fluid 
dynamics (CFD) methods have been used for greater hemodynamic detail (43–46).  
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Coupling of VAD CFD simulations to physiologic models has not yet been 
accomplished, but it may offer additional insight in future studies. 
This study aims to understand the physiological responses of stage 1 single 
ventricle patients to pulsatile and continuous flow VADs and identify mechanistic 
explanations for differences in performance under realistic physiological conditions.  
This will be evaluated on cohort and patient specific levels.  Recommendations for 
achieving optimal VAD performance in single ventricle patients will be provided within 
operational limitations of each type of VAD. 
Lastly, methods used in the stage 1 VAD study will be adapted to simulate resting 
and exercise physiologies of adults with normal bi-ventricular circulation.  Correlations 
for key physiological parameters with exercise level and body size will be developed 
using prior literature data.  Adjustments to parameters based on patient fitness level and 
age will also be incorporated as appropriate.  Then, the LPN will be tuned to match 
resting physiology reference data for an example patient.  Exercise physiology will be 
simulated for two example patients and compared with reference data.  This model can 
serve as a platform for simulating bi-ventricle physiology in future studies. 
 
Thesis Outline and Organization 
The research in this thesis explains the methodologies used to simulate stage 1 
single ventricle VAD supported physiology.  It examines key results and offers 
mechanistic explanations for their occurrences.  Lastly, these methods are adapted to 
simulate resting and exercise physiologies for example adult patients with normal bi-
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ventricular circulation.  Chapter Two explains the techniques of LPN modeling and 
Runge Kutta fourth order time-integration.  Chapter Three develops methods to model 
VAD supported physiology and the VADs themselves.  Chapter Four juxtaposes results 
for the pulsatile and continuous flow VADs at both the cohort and patient specific levels.  
Recommendations are also made for improving inferior VAD performance, and 
additional considerations of clinical interest are briefly examined.  Chapter Five discusses 
the important results and addresses limitations and areas for future work.  Chapter Six 
adapts several methods in Chapters Two and Three and develops additional correlations 
from prior literature data to simulate resting and exercise physiologies for an adult, bi-








Computational Modeling of Cardiovascular System 
 There are several prevailing options for modeling cardiovascular physiology. 
Computational fluid dynamics (CFD) methods typically use either finite volume or finite 
element techniques to create a three dimensional mesh of coupled nodes.  While CFD 
approaches achieve good accuracy and detailed hemodynamic data, the high 
computational time limits cardiovascular studies to local anatomies (43–46).  
Additionally, CFD coupling between a VAD and physiology model has not yet been 
accomplished.  Lumped parameter networks (LPN) and state space methods represent the 
circulation as a system of ordinary differential equations (ODE) and solve with numerical 
integration.  These methods have been used for local and large scale cardiovascular 
simulations (32–42) and have lower computational cost than CFD while maintaining 
comparable accuracy. 
 A LPN approach has several advantages over CFD for this particular study.  First, 
the exact geometry of the patient’s anatomy is not needed, which is especially valuable 
for a cohort study.  Instead, anatomical characteristics are “lumped” into the LPN 
elements to represent the average characteristics of a region, such as the aorta.  Second, 
the LPN is described with linear ODEs, which are solvable with computationally faster 
explicit time schemes.  CFD requires a mesh with sufficient nodes for convergence which 
increases computational time (47).  Third, clinical data is often reported by either mean or 
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minimum and maximum values.  Therefore, the finer hemodynamic detail achieved by 
CFD would be less valuable.  For these reasons, a LPN permits the simulation of a 
complete closed-loop cardiovascular system at low computational cost while still 
achieving desirable accuracy and detail.  A single ventricle LPN from a previous study 
will be the basis for the model developed in this thesis (34).  
 
LPN Modeling 
 To model physiology with a LPN, the electrical circuit elements must be 
translated into equivalent expressions in fluid mechanics. 
Resistors 
Assuming a no slip boundary condition at the vessel walls, a momentum 
exchange and dissipation occurs related to a fluid’s viscosity.  It is desired to obtain a 
form analogous to 𝑉 = 𝐼𝑅 in circuit analysis.  For steady state, axisymmetric, 
incompressible, laminar flow in a tube, the pressure change, ΔP, across a certain distance, 
l, is described by Hagen-Poiseuille flow 
∆𝑃 = '()
*+,
𝑄            (1) 
where µ is viscosity and r is tube radius.  Although exact dimensions of patient 
vasculature are unknown, Eq. (1) is a guide for determining physiologically appropriate 
equivalent resistance values for vascular beds. 
Capacitors 
 The capacitance of a fluid system is related to the elasticity or compliance.  




        (1) 
Inductors 
 Inductance describes the change in momentum of a fluid.  This is more important 
in pulsatile than steady flow.  Therefore, most inductor elements are found in the arterial 
circulation where flow has not yet been dampened.  By considering a control volume 
(CV) of inviscid fluid in a tube (Figure 1), conservation of linear momentum parallel to 
the flow direction produces 
𝑃1𝐴 − 𝑃4𝐴 =
567
68
             (3) 
𝐴(𝑃1 − 𝑃4) = 𝜌𝑙𝐴
67
68
     (4) 
∆𝑃 = 𝜌𝑙 67
68
         (5) 





         (6) 
Inductance, L, is the constant relating pressure drop to the time derivative of flow 
𝐿 = =)
>
       (7) 
Therefore, inductance increases with length and decreases with cross sectional area. 
 
 
Figure 1.  A control volume for an inviscid flow in a cylindrical tube 
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Runge Kutta Fourth Order Method 
 The Runge Kutta method is an explicit time-integration method to solve ODEs.  
This method is low in computational complexity and has fourth order error convergence 
for the particular scheme introduced here.  Four coefficients, Ki, are calculated at each 
simulation timestep, ti 
𝐾1 = 𝑓 𝑡D, 𝑥D             (8) 






𝐾1           (9) 






𝐾4         (10) 
𝐾J = 𝑓 𝑡D +
∆8H
4
, 𝑥D + ∆𝑡D𝐾I         (11) 
where xi is the current value of some variable, x, and Δti is the timestep size.  The value of 
the variable at the next timestep, xi+1, is calculated with a weighted sum of the 
coefficients 
𝑥DK1 = 𝑥D +
∆8H
L
𝐾1 + 2𝐾4 + 2𝐾I + 𝐾J     (12) 
 Initial conditions are needed for the first timestep since there is no prior history of 
the variables.  Initial conditions for pressure, flow, and volume are determined by making 
physiologically appropriate guesses and then using trial and error tuning until the LPN 






Overview of Study 
The LPN used to model patients in this study (Figure 2) was based on a previous 
work modeling Fontan patients (34).  To simulate a VAD support scenario, the VAD 
inflow and outflow cannulas were connected to the ventricle and aorta respectively.  A 
connection between the aorta and pulmonary arteries represented the systemic-to-
pulmonary shunt.  Respiration effects were not considered in these simulations. 
Clinical measurements from six stage 1 single ventricle patients (cohort mean 
body surface area (BSA) = 0.30 m2) were obtained from the Great Ormond Street 
Hospital, Medical University of South Carolina, and University of Michigan.  Flow 
measurements were obtained through MRI and ultrasound and pressure measurements 
through catherization and cuff techniques.  For the LPN simulations to accurately 
replicate each patient’s unique physiology, the LPN element values were tuned to match 
individual patient’s clinical measurements.  Once tuning of the pre-VAD LPN results was 
complete, ventricular contractility was set to zero to simulate heart failure. 
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Figure 2. Lumped-parameter network of stage 1 single ventricle circulation on VAD 
support.  PSUBSCRIPT, QSUBSCRIPT, LSUBSCRIPT, CSUBSCRIPT, RSUBSCRIPT, KSUBSCRIPT and 
ESUBSCRIPT represent pressure, volumetric flowrate, inductance, capacitance, linear 
resistance, quadratic resistance, and elastance respectively. 
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Simulation Setup and Protocol 
All simulations were run with a Runge Kutta fourth order time-integration method 
using FORTRAN to solve the governing system of ODEs of the LPN, and data were 
analyzed using MATLAB.  After simulations had reached periodicity, data from the last 
cardiac period were used in the analyses.  The pulsatile flow Berlin Heart EXCOR VAD 
and continuous flow HeartWare VAD were investigated in this study.  Cannula 
dimensions specified by the manufacturers for both VADs were used.  Variable VAD 
settings for the Berlin Heart were the device size, “heart rate” (HR), peak filling (PDIA) 
and ejection pressures (PSYS), and diastolic filling ratio (DFR), which is the time ratio of 
diastole to the total VAD period.  The only variable setting for the HeartWare VAD was 
revolutions per minute (RPM). 
Given these variables, two primary sets of simulations were done.  The first was 
designed to emulate current clinical implementation of VADs specific to stage 1 single 
ventricle patients and compare the performances of continuous and pulsatile flow VADs.  
The pulsatile flow VAD was simulated with the following ranges of settings:  HR (15-
105 BPM for 10 and 25 mL, 15-75 BPM for 50 mL), PDIA (-40 mmHg), PSYS (mean aortic 
pressure + 100 mmHg), and DFR (60%).  The continuous flow VAD was simulated over 
a range of rotor speeds from 1800-3400 RPM.	  
The second set of simulations investigated methods to further improve cardiac 
output by strategically changing the pulsatile flow VAD settings to ameliorate 
mechanisms limiting cardiac output.  This involved several modifications to peak 
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pressures and DFR.  All simulations were run for each patient in the cohort and the 
sample means were calculated. 
Statistics 
To determine statistical significance, hypothesis testing with p-values was done 
assuming a normal distribution.  For this study, the null hypothesis was that there is no 
difference between simulation results of two samples.  The p-value threshold for 
statistical significance was 0.05.  The t-statistic was used, and the probability for a two-
tailed distribution was calculated. 
 
Ventricular Assist Device Modeling 
Mathematical models were created to represent both VADs in the simulations.  
These models were created from experimental data and prior literature. 
Pulsatile Flow VAD 
 The Berlin Heart comes in several sizes ranging from 10 to 80 mL.  The 10 and 
25 mL sizes are common for pediatric use (11, 12), and the 50 mL size is also 
occasionally used to achieve higher CO.  Since the Berlin Heart is controlled directly by 
settings of the external air compressor, the model prescribed the VAD pressure, PCOMP, as 






	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑠𝑦𝑠𝑡𝑜𝑙𝑒
𝑃Xd> 𝑠𝑖𝑛
8W 1WXYZ ∗8[\] ∗*
XYZ∗8[\]
	  	  	  	  	  	  𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒
                     (13) 
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where tVAD is the time of one VAD period, and DFR is the diastolic filling ratio (a number 
between zero and one).  The air compressor is limited to drive HRs of up to 
approximately 110, 100, and 60 BPM for the 10, 25, and 50 mL sizes respectively.  With 
the pressure defined explicitly as a function of time, the volumetric flowrate entering or 
exiting the VAD can be calculated with Eq. (A2) in Appendix A. 
Continuous Flow VAD 
 For continuous flow VADs, blood is pumped at a constant rate and little 
pulsatility exists once equilibrium occurs between the VAD and the patient’s physiology.  
In general, cardiac output can be increased by increasing the VAD RPM.  Experimental 
data from literature was used for the HeartWare VAD to create quadratic trendlines 
(Figure 3) in the form of 
∆𝑃/>X = 𝐴𝑄/>X4 + 𝐵𝑄/>X + 𝐶          (14) 
where ΔPVAD is the pressure rise across the VAD, QVAD is the flowrate through the VAD, 




Figure 3. Reconstructed experimental data with quadratic best fit trendlines for the 
continuous flow HeartWare VAD 
 
Ventricular Suction Caused by VAD Operation 
The resistance due to ventricular collapse induced by a VAD shall be defined as 
the ventricular suction resistance, RSUC (mmHg s mL-1).  If the VAD attempts to draw 
blood from the ventricle below its reference volume, which results in a negative 
ventricular pressure, the ventricle begins to collapse.  When this occurs, ventricular tissue 
may be drawn into the cannula or the septum may be drawn closer to the cannula due to 
suction (48), both of which can inhibit blood flow into the VAD.  Several models have 
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been proposed in literature (49–56) to describe ventricular suction resistance induced by 
VADs in various animal experiments. 
A ventricular suction model (R2 = 0.72) suitable for the stage 1 single ventricle 
patients in this study was developed based on experimental data from several of these 
prior works (Appendix B) 
𝑅QhN =
0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑃Q/ > 𝑃kl
0.2623 0.97870r\s − 1 𝐵𝑆𝐴W^.IJv4	  	  	  	  	  	  	  	  	  	  𝑃Q/ ≤ 𝑃kl
               (15) 
where PCAN is the inflow cannula pressure, PSV is the ventricular pressure, PTH is the 
threshold pressure set to 0 mmHg, and BSA is the body surface area in m2.  In the event 
of complete flow obstruction, in which the inflow cannula attaches to the collapsed 
ventricular wall, PTH was updated to be the positive ventricular pressure needed to “pop 
off” the cannula from the wall.  This results in a recovery period when the ventricle fills 




             (16) 
where DCAN is the inflow cannula inner diameter (ID) in mm.  Developments of Eq. (15) 
and (16) are described in Appendix B. 
 
Passive Ventricular Pressure-Volume Relationship During Suction 
To properly utilize the ventricular suction model in Eq. (15), a passive ventricular 
pressure-volume relationship that can replicate a physiologically appropriate trend at 
negative pressures is required.  This has been investigated by several studies (57–59).  
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The results of Nikolić et al. were used since they presented sufficient supporting data to 
reconstruct a usable model for this study.  The pressure volume relationship is 
𝑃Q/ = 𝑆z ln
/}[
/}[~
            (17) 
where Sn is a stiffness property, VSV is the ventricular volume, and VSV0 is the reference 
volume for which ventricular pressure is zero.  The stiffness property in Eq. (17) was 







The pre-VAD simulation results (Appendix C) matched clinical measurements 
within ±10% for all six patients except for atrial pressure (up to ±30.6%) in three 
patients, pulmonary flow (up to ±19.8%) in two patients, and pulmonary pressure 
(±11.6%) in one patient.  However, clinical measurements of pulmonary flow were 
subject to fluctuations from turbulence in some patients, therefore convergence of other 
parameters to clinical measurements was sufficient to demonstrate that the LPN 
represented the patient physiologies well.	  
 
Simulation of VAD Implementation in Clinical Practice 
Pulsatile Flow VAD 
For a pulsatile flow VAD, the ideal theoretical cardiac output (CO) is VAD stroke 
volume (SV) times VAD HR.  This ideal CO was achieved for the 10 mL Berlin Heart at 
all HRs (Figure 4).  However, reductions in CO from ideal occurred at higher HRs for the 
25 and 50 mL sizes (Figures 4 and 5).  At very low HRs for the 10 and 25 mL sizes, 
additional flow through the aortic valve produced by atrial contraction resulted in CO 
greater than ideal; these scenarios would not be observed in reality since such low HR 
settings would not be used clinically. 
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The decrease in CO from ideal expectations in the 25 and 50 mL size Berlin Heart 
was examined more closely by investigating the VAD’s filling and ejection performance.  
For a pulsatile flow VAD to attain ideal CO, it must both fill and eject blood completely 
in each cardiac period.  Cohort mean stroke volumes (VMAX - VMIN) of the 25 and 50 mL 
sizes both showed decreases from ideal at higher HRs (Figure 6). 
 VMIN was 0 mL for all VAD sizes at all HRs, which implied that incomplete 
ejection never occurred.  Therefore, the observed drops in SV were solely due to 
incomplete filling.  For the 50 mL size from 45 to 75 BPM, VMAX decreased from 47.5 to 
33.2 mL despite a fairly constant suction resistance.  This implied incomplete filling was 
a combination of ventricular suction effects and reduced VAD diastolic time as HR 
increased.  It should be noted that CO continually increased with HR for both VAD sizes 
(Figures 4 and 5) despite the decreasing SV (Figure 6).  Therefore, using the highest HR 




Figure 4. Ideal (CO = SV*HR) and simulated CO of 10 and 25 mL Berlin Heart 
VAD HR (BPM)






















Figure 5. Resulting cohort mean physiology vs VAD settings for the 50 mL Berlin Heart 
and HeartWare VAD 
 
 
Figure 6. Cohort mean stroke volume (SV) and suction resistance (RSUC) vs VAD HR for 
25 and 50 mL Berlin Heart using clinical settings 
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Continuous Flow VAD 
 For a continuous flow VAD, RPM was the only variable setting.  CO produced by 
the HeartWare VAD increased steadily with RPM until reaching a maximum of 3.11 L 
min-1 at 3000 RPM (Figure 5).  Beyond 3000 RPM, complete flow obstruction began to 
occur as shown by the large increase in RSUC; this resulted in decreased CO.  Ventricular 
and atrial pressures both decreased steadily as unloading improved until reaching 
minimums of -2.88 and -0.52 mmHg at 3000 RPM.  The reduction in PSA occurred due to 
propagation of volume unloading upstream from the ventricle and demonstrated the 
VAD’s ability to alleviate congestion. 
 A phasic suction response occurred in three patients at high RPMs with the 
continuous flow VAD.  In those patients, PCAN approached negative pressures low 
enough (e.g. -200 mmHg) to result in complete flow obstruction where the ventricular 
wall was sucked onto the opening of the inflow cannula.  With no flow exiting the 
ventricle into either the VAD or aorta, ventricular pressure then increased as blood 
returned until a pressure, PTH, sufficient to “pop off” the cannula is reached and flow 
resumes.  This resulted in phasic behavior between periods of flow and complete flow 




Figure 7. Demonstration of phasic flow obstruction in one example patient during 
continuous flow VAD support 
 
Myocardial Stress Caused by VAD 
Myocardial recovery is of interest for patients ill-suited for transplant or when no 
donor heart is available.  It is assumed that optimal myocardial recovery occurs when 






                                                             (18) 
where hSV is the wall thickness of the ventricular tissue.  Wall thickness was calculated 
for each patient by developing an allometric correlation using prior literature data (60, 
61).  The mean ventricular stress was calculated for the 50 mL Berlin Heart and 
HeartWare VADs and plotted with CO (Figure 8). 



































Figure 8. Cohort mean CO vs ventricular wall stress for the 50 mL Berlin Heart and 
HeartWare VAD using clinical recommended settings 
 
 For the same CO, the pulsatile flow VAD produced lower mean ventricular stress, 
which may indicate better volume unloading.  However, the continuous flow VAD could 
produce higher CO, which resulted in lower minimum stresses than possible with the 
pulsatile flow VAD.  If considering the same stress, the continuous flow VAD also 
produced at least 0.15 L min-1 greater CO.  Only when flow for the continuous flow VAD 
became obstructed from ventricular suction (the bottom red tail) were outcomes similar 
between VADs.  This supports the hypothesis that continuous flow VADs can produce 
better patient outcomes with minimal stress on the myocardial tissue (27, 31).  The 
derivative of stress with respect to CO was also comparable between VADs.  This may 
suggest the relation between ventricular pressure and volume with CO is independent of 
CO (L min-1)




















50 mL Berlin Heart
HeartWare
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the type of VAD used.  Also of note, stress became negative for the continuous flow 
VAD as CO approached its maximum.  Evaluation of potential effects of prolonged 
compressive stress on the heart tissue during VAD support may require further clinical 
study. 
 
Simulation of VAD Settings Intended to Further Increase Cardiac Output 
 Pulsatile flow VAD settings different from current clinical implementation were 
also tested with the goal to maximize CO.  Investigations were done with the 50 mL 
Berlin Heart only since the mean CO was as much as 1.4 L min-1 (37.3%) below ideal 
(compared to 0% and 9.7% for the 10 and 25 mL sizes).  Since incomplete filling was 
identified as the limiting factor to CO for the Berlin Heart, adjustments were made to 
peak VAD pressures and DFR to improve filling performance.  It is not possible to 
increase the VAD cannula ID to reduce flow resistance due to surgical limitations of the 
pediatric ventricle.  These modifications and combinations of VAD settings were 
simulated for all patients.  Results at 60 BPM produced the highest cardiac index (CI) in 
all cases while remaining within the limits of the air compressor (Table 1). 
 
Table 1.  Results of modifications to settings for 50 mL Berlin Heart (* indicates 
statistical significance at p < 0.05) 
Case VAD Setting Change Rationale Mean CI                 (L min-1 m-2) 
Mean RSUC                        
(mmHg s mL-1) 




A Control  7.63 0.06   
B PDIA = -100 mmHg 
Larger pressure gradient 
for filling 7.63 0.12 1.0000 1.940·10
-5* 
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C DFR = 65% Increased time for filling 7.64 0.07 0.9854 0.1902 
D PDIA = -100 mmHg DFR = 65% Combine cases B and C 7.65 0.13 0.9707 3.706·10
-6* 
E 
PSYS = PAO+200 mmHg 
PDIA = -100 mmHg 
DFR = 65% 
Incomplete ejection 
occurred in case D, thus 
increased peak ejection 
pressure 
7.73 0.13 0.8777 8.992·10-7* 
F 
PSYS = PAO+200 mmHg 
PDIA = -100 mmHg 
DFR = 80% 
Further increased time for 
filling 7.81 0.16 0.7729 6.018·10
-9* 
 
 None of the modifications to pulsatile flow VAD settings produced statistically 
significant differences from clinical implementation (control) simulations with respect to 
CI, and the best result produced only a 2.4% increase in CI.  When combining the PDIA = 
-100 mmHg and DFR = 65% settings (case D), filling improved enough to result in 
nonzero VMIN, which signaled incomplete ejection.  Thus, PSYS was further increased to 
improve ejection (case E).  Next, DFR was increased to 80% to further increase time for 
filling, which produced another 1.0% increase to CI (case F).  Statistically significant 
increases in RSUC did occur in most cases though since improved filling increased the 
VAD’s demand for blood from the ventricle. 
Simulation of Modified Inflow Cannula Positioning 
 A contributing factor to incomplete filling not yet explored is pressure loss caused 
by inflow cannula position.  The position of the cannula tip relative to the inner 
ventricular wall affects the minor loss coefficient, kL, (Figure 9) and consequently the 
pressure loss predicted by Eq. (A17).  In clinical implementation, the cannula head length 
is fixed and excess length protrudes into the ventricle for most every patient.  However, if 
the tip of the inflow cannula were instead flush with the inner ventricular wall, kL would 
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decrease from 0.8 to 0.5 (62).  This would result in a 37.5% lower pressure drop across 
the cannula and could consequently improve CO. 
 
 
Figure 9.  The minor loss coefficient for an inflow cannula extending beyond and flush 
with the inner ventricular wall 
  
Two simulations were run for each patient with this reduced kL factor.  The first 
simulation used the clinical recommended VAD settings (case A, Table 1), and the 
second simulation used the modified VAD settings that produced highest CI (case F).  
With kL reduced to 0.5, mean CI were 7.63 and 7.81 L min-1 m-2 for cases A and F 
respectively, which matched results when kL was originally 0.8.  Upon further review, the 
pressure losses for either kL factor were typically less than 1 mmHg and had negligible 
effect on patient outcomes in both cases.  Therefore, an improvement to the inflow 
cannula position is unlikely to produce a noticeable improvement in VAD filling. 
 
Patient Specific Results 
 The optimal patient specific results from VAD treatment were investigated to 
identify patient specific factors affecting outcomes and the differences between pulsatile 
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and continuous flow VAD support at an individual level (Table 2).  Detailed 
physiological results of these simulations are in Appendix D. 
 
Table 2. Optimal patient specific results for pulsatile and continuous flow VADs.  All 
units for CO are L min-1.  NI denotes “no improvement.” 
Patient A B C D E F 
Pre-VAD CO 1.29 1.55 1.42 1.60 1.87 1.75 
Desired VAD CO 3.00 2.60 3.40 2.80 3.40 2.70 
       
a) Pulsatile Flow 
Control CO 1.92 2.30 2.14 2.24 2.21 2.79 


















PSYS = 200+ 
PAO mmHg  






PSYS = 200+ 
PAO mmHg  





PSYS = 200+ 
PAO mmHg  
PDIA = -100 mmHg 
80% DFR 
b) Continuous Flow 
Control CO 3.11 3.37 3.36 3.51 3.31 4.09 
Rotor RPM 3400 3200 3000 3200 3400 3400 
 
Due to volume loading from the pulmonary shunt, significant CO is desired to 
produce favorable clinical outcomes.  The desired VAD CO for these pediatric patients 
was BSA*CI, where the desired CI was 10 L min-1 m-2.  The desired CO was attained for 
1 of 6 and 4 of 6 patients for pulsatile and continuous flow respectively.  For all six 
patients, the optimal continuous flow VAD outcomes resulted in at least 1 L min-1 greater 
CO than the corresponding optimal pulsatile flow VAD outcomes.  Modifying the 
settings of the pulsatile flow VAD increased CO for four patients, but the largest increase 
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was only 0.07 L min-1 (3.0%).  Therefore, clinically recommended settings had already 
produced very close to optimal results for pulsatile flow support. 
Pre-VAD CO was the best predictor of VAD supported CO for both VAD types 
(R2 = 0.42 for pulsatile, 0.28 for continuous).  This was true for each patient in the cohort 
except for patient E.  Patient E had an atrial reference volume (P = 0 mmHg) of 14.1 mL 
compared to a mean of 1.4 mL for the other five patients.  This required a comparatively 
larger atrial volume to maintain an atrial pressure sufficient to drive ventricular filling.  
This reduced the VAD CO for patient E because the atrium could collapse more easily 
than those of other patients. 
The 25 mL size produced optimal CO for the pulsatile flow outcomes in three 
patients.  Two of these patients (A and C) possessed the lowest pre-VAD CO and the 
other was patient E who possessed the larger atrial reference volume.  Since the 25 mL 
size required half as much filling per VAD period to produce the ideal CO compared to 
the 50 mL size, the likelihood of incomplete filling was reduced.  This result suggests 
using a smaller size pulsatile flow VAD for patients with low pre-VAD CO. 
 Complete flow obstruction occurred in three patients with the HeartWare VAD.  
These patients had three of the four lowest pre-VAD CO.  This indicates that optimal 
outcomes for patients with low pre-VAD CO will occur at lower VAD RPM settings. 
 
Simulation of Pseudo-Pulsatile Flow Generated by Continuous Flow VAD 
 Although the pulsatile flow VAD produced lower CO than the continuous flow 
VAD in all patients, pulsatile flow provides a more favorable environment for cellular 
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biology and the endothelium (21, 24, 63).  Therefore, the operation of a continuous flow 
VAD in a pseudo-pulsatile mode can produce more natural physiology while maintaining 
surgical advantages of continuous flow VAD implementation.  As a proof of concept, 
continuous flow VAD RPM was dynamically changed during simulations to emulate step 
and triangle functions.  The resulting physiologies were compared with the closest 




Figure 10. Resulting physiology for one example patient using the pulsatile flow VAD 
and the continuous flow VAD with constant, step, and triangle RPM functions 
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The step and triangle RPM functions produced mean CO of approximately 2.32 
and 2.24 L min-1 compared to 2.22 L min-1 with a constant RPM setting.  Each of these 
outcomes were superior to the optimal pulsatile flow outcome for this patient (2.14 L 
min-1).  The continuous flow VAD also overcomes the pulsatile flow VAD’s limitation in 
maximum HR and can synchronize to the patient’s resting HR (120 BPM) while the 25 
mL pulsatile flow VAD was limited to 90 BPM.  This may be advantageous for patients 
with some ventricular contractility present during VAD support.  These initial data 
suggest a continuous flow VAD can produce pseudo-pulsatile flow and better patient 
outcomes than a pulsatile flow VAD. 
 
Comparison Between Axial and Centrifugal VAD Designs 
 Axial and centrifugal continuous flow VADs theoretically produce the same 
steady flow, but their pump curves are linear and quadratic respectively.  The axial design 
HeartMate II VAD and centrifugal design HeartWare VAD were simulated for the same 
example patient at each RPM for which literature data existed to construct a trendline.  
Both VADs produced the same qualitative results (Figure 11), although the RPM needed 
to produce a particular CO varied by VAD (e.g. 2400 for HeartWare, 9000 for HeartMate 
II).  The resulting physiologies for similar CO with both VADs are shown in Table 3 and 
further suggest similarity in patient outcomes between axial and centrifugal designs. 
Although flow obstruction never occurred with the HeartMate II VAD, this is 
attributable to a lack of literature data for this VAD at higher RPMs.  Maximum CO 
before flow obstruction for the HeartWare VAD was 3.36 L min-1, but the HeartMate II 
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VAD only produced up to 3.24 L min-1 in the simulated RPM range.  Therefore, it is 
expected that a slightly higher RPM (e.g. 11000 RPM) with the HeartMate II VAD could 
result in flow obstruction. 
 
 
Figure 11. Resulting physiology for one example patient using the centrifugal HeartWare 
and axial HeartMate II continuous flow VADs 
 
Table 3.  Mean physiological results for centrifugal HeartWare and axial HeartMate II 
VADs for same approximate CO 
Parameter HeartWare HeartMate II Abs Diff 
CO (L min-1) 2.55 2.58 0.03 
VSA (mL) 2.78 2.23 0.55 
VSV (mL) 3.40 3.33 0.07 
PSA (mmHg) 0.30 0.15 0.15 
PSV (mmHg) -0.96 -1.15 0.19 
PAO (mmHg) 71.26 72.02 0.76 
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PPA (mmHg) 12.06 12.00 0.06 
QP/QS 0.35 0.35 0.00 







It is dominantly observed in anecdotal clinical experiences of VAD support in 
single ventricle patients that continuous flow results in superior clinical outcomes.  
However, these clinical experiences are rare and have not been well documented or 
published.  This computational study provides crucial data as an important first step to 
understand the physiological impacts of continuous versus pulsatile flow VAD support to 
the single ventricle circulation and to illustrate the potential underlying mechanisms 
leading to these impacts. 
Following clinical protocol, the maximum cohort mean CO were 2.23 and 3.11 L 
min-1 with the Berlin Heart and HeartWare VAD respectively.  With modifications to the 
pulsatile flow VAD settings, mean CI increased by at most 2.4% and still remained below 
the desired CI.  The mean atrial and ventricular pressures decreased from 11.36 and 14.83 
mmHg during pre-VAD HF (Appendix D) to 1.90 and 0.29 mmHg (Berlin Heart) and -
0.52 and -2.88 mmHg (HeartWare VAD) during optimal VAD support.  These results 
demonstrated that, while congestion was alleviated with both pulsatile and continuous 
flow VAD support, the continuous flow VAD produced superior maximum CO 
(p=0.0009).  These findings corroborate current clinical experience of VAD 
implementation in single ventricle patients.  The effects of negative cardiac pressures on 
the tissue during VAD support may require further clinical study. 
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The concept of duty cycle can explain why continuous flow produced superior 
CO to pulsatile flow.  The continuous flow VAD effectively has a 100% duty cycle since 
filling and ejection are synonymous.  The pulsatile flow VAD has a reduced duty cycle 
since it can only fill or eject at any given time, and the optimal DFR could vary in each 
clinical scenario. 
Other challenges to attaining ideal CO for pulsatile flow in clinical practice can 
also be identified.  For the 25 and 50 mL Berlin Heart, incomplete filling presented at 
higher HRs because time for filling was reduced.  Producing a high CO with a pulsatile 
flow VAD necessitates using a high HR, which then results in incomplete filling.  Despite 
testing several modifications to VAD peak pressure and DFR settings, the VAD’s 
increased demand for blood only tended to produce greater suction resistance rather than 
CO.  Incomplete ejection is another potential limiting factor to CO.  However, since 
ejection occurs separately from filling, PSYS can be increased to eliminate incomplete 
ejection with no adverse effect on filling performance.  This was successfully 
demonstrated during the simulations of modified pulsatile flow VAD settings when PSYS 
was increased by 100 mmHg from clinical recommendation to prevent incomplete 
ejection (case E, Table 1).  Therefore, incomplete ejection should generally not be a 
limiting factor of CO for a pulsatile flow VAD. 
 
Limitations and Future Work 
Since there is a lack of ventricular suction data specific to pediatric, single 
ventricle patients, the new suction model will require experimental validation in future 
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studies.  Despite this, results from suction model simulation testing (Appendix B) did 
provide confidence that the proposed model improved over existing models at producing 
physiologically realistic results.  Additionally, the new model accounted for the 
possibility of complete flow obstruction, which prior models did not.  Even though Eq. 
(15) was developed from an amalgam of data for various anatomies, it is strongly 
recommended that future computational studies employ a similar validation process as 
described in Appendix B for the selection of an appropriate model. 
There remains a need for improvement of models describing ventricular suction 
resistance and the passive pressure-volume relationship at negative ventricular pressures.  
The majority of existing work has focused on animal experiments, and it is unknown how 
well these translate to humans.  It could be beneficial to explore in-vivo experiments and 
human data in future studies.  This would provide much needed advancements to critical 
components of computational simulations involving VADs.  While in-vitro experiments 
with postmortem hearts could be orchestrated more easily, the lack of muscle tone and 
tissue would not be representative of a clinical situation.  Additionally, it would be 
beneficial for future computational studies to incorporate cardiovascular feedback 
mechanisms to simulate a patient’s long-term response to VAD treatment.  This study 
simulates immediate post-op physiology, which may change as the patient adapts to VAD 
treatment. 
Since ventricular contractility may be partially present during HF, 
synchronization of the VAD to the patient’s native heart can impact the efficacy of filling 
and ejection and consequently CO.  Synchronization of pulsatile and pseudo-pulsatile 
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ADAPTATIONS TO FUTURE WORK 
 
Introduction 
The LPN used in Chapters 3-5 modeled a single ventricle circulation.  However, a 
single ventricle congenital heart defect occurs in approximately 1 per 2000 births in the 
United States (64).  Therefore, developing a LPN for a normal bi-ventricular circulation 
enables future studies for a larger patient population. 
The new LPN (Figure 12) was created with several modifications to the single 
ventricle LPN.  In the bi-ventricular circulation, the right heart, lungs, and left heart are 
connected in series.  Therefore, the systemic-to-pulmonary shunt in the stage 1 LPN was 
removed, and another atrium-ventricle pair were added between the vena cava and 
pulmonary artery.  The effects of respiration were included by coupling appropriate 
pressures to the intrathoracic pressure, Pith. 
A simple coronary model was added with a branch connecting the aorta and right 
atrium.  Coronary flow is also unique in that the peak value occurs during diastole.  
Ventricular contraction during systole causes constriction of the coronary vessels, which 
are located on the exterior surfaces of the heart, and increases the resistance to coronary 









Correlations with exercise level and body size for physiological parameters can be 
developed using prior literature data.  This includes HR, total vascular resistance (TVR), 
pulmonary vascular resistance (PVR), metabolic equivalent (MET), and several cardiac 
parameters.  These correlations will be packaged into a similar protocol as a parent study 
that simulated exercise physiology in single ventricle adults (34).  Considerations for 
patient fitness level and age will also be introduced as appropriate.  All correlations in 
this section are derived from studies of healthy adults primarily in their twenties. 
The first equation computes BSA (in m2) from patient height and body mass 
inputs via the Mosteller equation 
𝐵𝑆𝐴 = lD8∗P
IL^^
              (19) 
where height is in cm and mass is in kg. 
 It is desired to relate a normalized indication of exercise level to an absolute 
exercise workload, such as Watts, for comparing data of disparate patient sizes.  Exercise 
level can be reported in terms of metabolic equivalent task (MET), which is defined as 
3.5 mL O2 min-1 kg-1.  After adapting data from Jetté et al. of MET versus applied power 
for a 70 kg human (65), the following linear correlation (R2 = 0.99) is developed 
𝑀𝐸𝑇 = 4𝑃𝑊𝑅 + 1             (20) 
where PWR is the ratio of applied power to body mass in W kg-1.  Select examples of 
common exercises and the equivalent MET are in Appendix E. 
 Next, HR and TVR can be normalized by body mass and correlated with exercise 
level.  It is established for mammalian species that HR scales with M-0.25 (66) and TVR 
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with M-0.75 (67).  HR data were extracted from three studies and TVR data from 
Strickland et al. (68–70).  Each study investigated healthy adults, most of whom were in 
their twenties, and grouped patients by fitness level, so separate correlations for low and 
high fitness can be developed.  There is no agreed upon distinction between low and high 
fitness, however Strickland grouped patients by whether maximum exercise capacity (i.e. 
VO2 max) was less than (low fitness) or greater than (high fitness) 55 mL O2 min-1 kg-1.  
Using linear fits for HR (R2 = 0.95, 0.88) and power fits for TVR (R2 = 0.99, 0.99), the 
best fit correlations are 
𝐻𝑅 = 1
P~.x
28.029𝑀𝐸𝑇 + 179.62	  	  	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
19.518𝑀𝐸𝑇 + 194.43	  	  	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠                      (21) 
𝑇𝑉𝑅 = 1
P~.
484.28𝑀𝐸𝑇W^.JJ4	  	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
468.47𝑀𝐸𝑇W^.I^	  	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
           (22) 
where HR is in units of BPM, TVR in units of mmHg min L-1, and M in kg. 
 A correlation for PVR is also needed.  Using TVR and PVR data from the same 
study by Strickland, correlations (R2 = 0.99, 0.98) relating the two can be developed for 
low and high fitness levels 
𝑃𝑉𝑅𝑓 = 0.3742 ln 𝑇𝑉𝑅𝑓 + 1	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠0.5238 ln(𝑇𝑉𝑅𝑓) + 1	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠           (23) 
where the suffix, f, denotes the scale factor of TVR or PVR from values at rest (i.e. 
TVR/TVRREST).  As MET increases, TVR decreases from its resting value (Eq. (22)), and 
thus PVRf (and PVR) decrease as well. 
The capacitance must also be adjusted for body mass.  Using allometric reasoning 






W,         (24) 
where the subscript i indicates the reference value before scaling.  The capacitance must 
also be scaled based on exercise level.  Based on the same previous studies, the 





W,         (25) 
The total intrathoracic pressure is modeled by Eq. (A18), but its subcomponents 
can be calculated using data from Grimby et al. at two exercise levels (73).  Correlations 
for the pressure amplitude, APith, and offset, Pith,offset, were 
𝐴𝑃D8 = −3.9𝑀𝐸𝑇             (26) 
𝑃D8,8 = 1.92 𝑀𝐸𝑇 − 1 − 3.7             (27) 
where both parameters are in units of mmHg. 
Cardiac index can be predicted by relative volumetric flow of oxygen or VO2.  
Using data again from Ekblom, Gledhill, and Strickland for low and high fitness levels 
(68–70), best fit linear correlations (R2 = 0.91, 0.97) were 
𝐶𝐼 = 203.7𝑉𝑂4 + 3.4549	  	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠232.5𝑉𝑂4 + 2.6277	  	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
        (28) 
where VO2 is in units of L O2 min-1 kg-1 and CI in units of L min-1 m-2.  This correlation 
does not prescribe CI during simulations; it only enables an estimate for CI when clinical 
data are not available. 
Cardiac Parameters 
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Unlike the stage 1 VAD study, an elastance function (Eq. (A21)) will be used to 
model ventricular contractility.  Advantages of the elastance function are that the 
normalized shape is independent of contractile state (e.g. HR, age, or disease factors) and 
it can be scaled with exercise more easily than an active-passive model (74).  The 
elastance function includes parameters describing the heart’s contractility, such as EMAX 
and EOFFSET, and the total ventricular systolic time, tvs.  Gemignani et al observed an 
approximately linear decrease in tvs until reaching a plateau at approximately 120 BPM 




120 − 𝐻𝑅 ∗ L^
lZ
	  	  	  	  	  	  	  	  	  	  	  	  	  𝐻𝑅 ≤ 120	  𝐵𝑃𝑀
0.5 ∗ L^
lZ
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝐻𝑅 > 120	  𝐵𝑃𝑀
       (29) 
where tvs is in units of seconds. 
 Lastly, several correlations are needed for cardiac parameters that either do not 
have sufficient data to create a correlation or lack physical meaning.  This includes the 
maximum cardiac contractility, EMAX, the elastance offset, EOFFSET, the right and left 
ventricular reference volumes, VRV0 and VLV0, and the scale factor of the initial conditions, 
PRATIO.  A range of constants was tested for each of these correlations and numerical 
iteration selected the combination minimizing the total percent error between LPN results 
and reference data adapted from literature (Table F2) (68–70).  Those correlations are 
presented below and qualitatively agree well with the constants used in the parent study 
𝐸P> =
𝐵𝑆𝐴 0.10𝑀𝐸𝑇 + 1.2174 	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
𝐵𝑆𝐴 0.05𝑀𝐸𝑇 + 1.2674 	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠  (30) 
𝐸OYYQk =
−0.0045𝑀𝐸𝑇 + 0.08115	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
−0.0075𝑀𝐸𝑇 + 0.08414	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠   (31) 
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𝑃Z>kdO =
0.23𝑀𝐸𝑇 + 0.77	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
0.22𝑀𝐸𝑇 + 0.78	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠        (32) 
𝑉Z/^ =
10𝐵𝑆𝐴 + 40.264	  	  	  	  	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
100𝐵𝑆𝐴 − 137.36	  	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠         (33) 
𝑉/^ =
10𝐵𝑆𝐴 − 26.736	  	  	  	  	  	  	  	  𝑙𝑜𝑤	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠
70𝐵𝑆𝐴 − 145.15	  	  	  	  	  	  ℎ𝑖𝑔ℎ	  𝑓𝑖𝑡𝑛𝑒𝑠𝑠        (34) 
where EMAX, EOFFSET, PRATIO, VRV0, and VLV0 are in units of mmHg mL-1, mmHg mL-1, 
unitless, mL, and mL respectively.  The reference volumes do not scale with MET since 
they are anatomical properties. 
Age Considerations 
 Age related effects can also be incorporated with appropriate adjustments to the 
correlations for physiology and cardiac parameters.  Each of the age related correlations 
presented below, except EOFFSET and PRATIO, was developed using literature data.  If a 
correlation was given for an age range (e.g. middle age defined in a study as 35-46 
years), then the correlations in the previous section should be used for the lowest age 
range (e.g. 34 years and under). 
First, HR tends to decrease with age (76–80).  Using clinical data adapted from 
Tulppo et al. (81) for three fitness controlled age groups, correlations for those middle 
(35-46 years) and old (47-64 years) age groups can be derived.  The ratios of mass 
normalized HR between young adults and the middle and old age adults were calculated 
at multiple exercise levels (e.g. middle HR/young HR for several matching MET values).  
The best fit (R2 = 0.99, 0.99) power models were 
𝐻𝑅Z>kdO =
1.0096𝑀𝐸𝑇W^.^4L	  	  	  	  	  (35 ≤ 𝐴𝑔𝑒 < 47)
0.8744𝑀𝐸𝑇W^.^14	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (47 ≤ 𝐴𝑔𝑒)
  (35) 
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where HRRATIO is multiplied by the HR predicted in Eq. (21). 
Vascular resistance may (76, 79, 82) or may not increase with age (77, 83), 
however data presented by Slotwiner et al. demonstrated a statistically significant 
increase in SVR with increasing age (82).  There was insufficient exercise data for 
different ages to include exercise level in the correlation, so it is assumed for now that the 
correlation remains true at different exercise levels.  It is also assumed that SVR and 
TVR increase similarly, since literature data did not exist for both SVR and PVR or just 
TVR only.  Study participants were not separated into age groups, so the logarithmic best 
fit (R2 = 0.97) correlation with age is 
𝑇𝑉𝑅Z>kdO = 0.2799 ln 𝐴𝑔𝑒 + 0.0208	  	  	  	  	  (𝐴𝑔𝑒 > 34)   (36) 
where TVRRATIO is multiplied by the TVR predicted in Eq. (22) and age is in years.  
Equation (36) should be used only for ages greater than thirty-four years to prevent 
calculating a ratio less than unity for younger patients. 
Aortic capacitance decreases with age due to decay of flexible elastin fibers and 
produces elevated systolic blood pressure (84–87).  Mohiaddin et al. provided a best fit 
correlation for capacitance of the large arteries; this was normalized by the capacitance of 
a twenty year old and found to be 
𝐶Z>kdO = 1.5849𝑒W^.^4I>       (37) 
where CRATIO is multiplied by capacitance elements of the large arteries (CAO, CTHAO, 
CABAO).  Rates of change in capacitance at different sections of the aorta were observed to 
be similar, so Eq. (37) should be equally applicable to each of these capacitor elements in 
the LPN. 
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Due to aortic stiffening, ventricular mass and contractility increase to maintain 
adequate CO (82).  Using data from Slotwiner for contractility at several ages, the 
contractility was normalized by that for a thirty-four year old (youngest in study) and the 
best fit (R2 = 0.99) linear correlation was 
𝐸P>,Z>kdO = 0.0034𝐴𝑔𝑒 + 0.8853	  	  	  	  	  (𝐴𝑔𝑒 > 34)             (38) 
where EMAX,RATIO is multiplied by EMAX predicted in Eq. (30).  Thirty-four years was the 
youngest age in the study, so Eq. (38) should be used only for the ages greater than or 
equal thirty-four to prevent calculating a ratio less than unity for younger patients.  
O’Rourke observed an increase in systolic time with age (87).  Using a linear 
correlation for the two patients, this is estimated to be 
𝑡7,> = 𝑡7,ZY + 0.001152𝐴𝑔𝑒	  	  	  	  	  (𝐴𝑔𝑒 > 36)           (39) 
where tvs,AGE is the adjusted systolic time for a particular age and tvs,REF is the systolic 
time predicted by Eq. (29).  Thirty-six years was the younger age in the study, so Eq. (39) 
should only be used for ages greater than or equal thirty-six. 
A review of CO change with increasing age has presented conflicting findings 
(82), although a decreasing CO with increasing age is possible.  Due to this uncertainty, 
an age related adjustment for CO was not developed.  Future studies can add and edit 
considerations for patient age as needed.  These were included as they capture several 
cardiovascular changes due to aging with sufficient data and agreement in literature.   
Age related adjustments to the parameters of EOFFSET and PRATIO were obtained 
through tuning for the same example patients as the previous section at three different 
ages (25, 45, and 65 years).  Since insufficient literature data existed across a wide age 
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range at multiple exercise levels, manual tuning via visual inspection was done to 
produce the correct qualitative changes in physiology with increasing age.  These trends 
included decreased CO (82), increased pressure (77, 79, 83, 88), and decreased SV (80).  
The age adjusted equations best producing these effects in both patients were 
𝐸OYYQk,> = 𝐸OYYQk,ZY ∗ 1 − 0.013𝐴𝑔𝑒 	  	  	  	  (𝐴𝑔𝑒 ≥ 30)       (40) 




The bi-ventricular LPN was tuned for a resting condition (MET=1) using an 
example patient with comparable BSA to the studies used to obtain exercise correlations.  
The desired tolerance for each parameter was ±2.00 in the corresponding units for each 
parameter in Table F1 from the corresponding reference value.  A percentage tolerance 
was not used since this would produce excessive bias (e.g. 10% of 1 mmHg and 100 
mmHg are 0.1 and 10 mmHg) for the tuning of biventricular resting physiology.  The 
new LPN matched reference values within tolerance for most parameters (Table F1).  
One type of parameter outside the tolerance was the minimum cardiac pressures.  The 
LPN produced lower minimum pressures due to subtraction of Pith from each cardiac 
pressure.  The mismatch was partially alleviated by multiplying Pith by a fraction of unity, 
which physically represented the negative thoracic pressure being partially transmitted to 
the heart blood volume across the myocardium.  No literature was found to directly 
support this, so future study may be needed.  The other deviations occurred for the end 
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diastolic and end systolic volume indices (EDVI and ESVI) of both ventricles.  However, 
for both ventricles, the LPN approximately produced the correct mean volumes.  While 
improvements could be added for future work, these results gave sufficient confidence to 
proceed with preliminary modeling of exercise physiology. 
Example Exercise Physiologies 
 The LPN was first tested by simulating two example low fitness patients of 
different BSA at three exercise levels.  The reference data from literature (Table F2) used 
for comparison included CO, mean arterial pressure (MAP), pulmonary center wedge 
pressure (PCW), and SV (68–70).  CO and SV data were normalized by body mass as 
appropriate (66) to enable unbiased comparison of data between LPN and prior clinical 
studies.  Therefore, the parameter type (pressure, flow, and volume) sensitivities now 
differ greatly, so the value of an absolute tolerance would need to vary by type (e.g ±2 
mmHg versus ±0.1 L min-1 kg-0.75).  The percent difference between LPN and reference 
data was reported instead since MAP and PCW are of the same order of magnitude (which 
reduces bias) and CO and SV are both normalized by body mass in some way. 
 For both patients, CO, pressure, and SV each increased with exercise level as 
expected (Figure 13).  Also as expected, CO and SV were higher for the larger patient 
(Patient B) while pressures were comparable between patients (pressure is invariant of 
body mass (66)).  Comparisons between LPN results and reference data show CO and 
MAP matched reference data within 10% for both patients (Table 4), but larger errors 
occurred for PCW and SV.  Strickland observed nonlinear increases in pulmonary 









needed in future work to accurately model pulmonary pressure.  The error in SV can be 
attributed to the original LPN tuning, which had slightly overpredicted SV for both 
ventricles (Table F1). 
 
Table 4. Simulation results and absolute percent differences between LPN and reference 
data for two example low fitness patients 
a) Example Patient A: Mass = 60 kg, Height = 170 cm 
Simulation Results 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.45 95.10 15.43 2.00 
8 0.70 105.80 21.62 2.08 
12 1.02 125.32 25.46 2.42 
     
Percent Differences 
4 9.20 0.05 66.86 21.02 
8 6.07 0.70 80.16 9.95 
12 2.53 8.91 4.85 28.63 
     
b) Example Patient B: Mass = 79 kg, Height = 177.5 cm 
Simulation Results 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.48 97.22 14.65 1.96 
8 0.67 98.77 21.00 1.90 
12 0.96 115.45 24.07 2.03 
     
Percent Differences 
4 3.15 2.28 58.43 18.60 
8 10.09 5.99 75.00 0.43 
12 3.50 0.33 0.88 7.90 
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Simulations were repeated for the same two example patients but with a high 
fitness level.  The LPN results matched CO within 10%, but deviation increased for MAP 
and PCW (Table 5).  The increased deviation may be due to nuances of high fitness 
physiology not accounted for in these models.  However, the high fitness physiology 
produces the correct qualitative trends (Figure 14).  Despite a lower HR in high fitness 
level simulations, flow remained comparable to those in low fitness simulations.  This is 
due to the lower resistance of high fitness patients predicted by Eq. (22) and increased SV 
(CO = SV*HR). 
 
 
Figure 14. Physiology tracings of two example patients for low and high fitness levels for 
the last respiration cycle at MET = 8 
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Table 5. Simulation results and absolute percent differences between LPN and clinical 
data for two example high fitness patients 
a) Example Patient A: Mass = 60 kg, Height = 170 cm 
Simulation Results 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.48 87.80 15.58 2.00 
8 0.69 86.17 22.97 2.08 
12 1.01 99.25 27.47 2.42 
     
Percent Differences 
4 6.67 9.58 84.16 21.95 
8 2.82 15.25 209.57 1.05 
12 4.12 6.60 239.14 13.08 
     
b) Example Patient B: Mass = 79 kg, Height = 177.5 cm 
Simulation Results 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.50 86.98 14.79 2.15 
8 0.66 82.36 21.84 2.15 
12 0.94 90.09 26.53 2.47 
     
Percent Differences 
4 11.11 10.42 74.82 31.10 
8 7.04 19.00 194.34 13.76 
12 3.09 15.22 227.53 15.42 
 
 
Simulations were repeated again for the same two example patients at a low 
fitness level and three ages.  Overall, the qualitative trends were reproduced well by the 
LPN (Table 6).  For both patients, CO decreased and PCW increased as age increased, as 
expected. MAP and SV also showed the correct trends, although one exception occurred 
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out of four cases for both MAP and SV.  Peak aortic flow (QAO) also noticeably 
decreased in both patients as age increased due to the increasing systolic time for ejecting 
to occur (Figure 15).  These results can be improved in future works by tuning parameters 
to clinical data for a particular patient cohort under investigation. 
 
 
Figure 15. Physiology tracings for two example low fitness patients at three ages for the 
last respiration cycle at MET = 8 
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Table 6. Percent differences for two example low fitness patients with respect to 
reference data at age 25 for MET = 8 (+/- used to denote age related change from 
reference data of Table F2; + indicates increase from reference value and ++ indicates 
larger increase from reference value) 
a) Example Patient A: Mass = 60 kg, Height = 170 cm 
Percent Differences 
Age CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
45 -22.9 1.6 66.7 -22.2 
65 -32.9 -1.9 88.9 -24.9 
     
b) Example Patient B: Mass = 79 kg, Height = 177.5 cm 
Percent Differences 
45 -20.9 2.4 66.7 -20.2 
65 -25.4 6.0 84.8 -18.0 
     
Clinically Observed Qualitative Trends 
45 - + + - 
65 -- ++ ++ -- 
 
Pediatric Case Study 
 The LPN was tested further by simulating a clinical scenario of a pediatric bi-
ventricular patient with left ventricular (LV) dysfunction.  To promote LV recovery, 
clinicians placed a restrictive band around the pulmonary artery to increase resistance just 
downstream of the right ventricle (RV).  It was hypothesized this would increase RV 
pressure and thus push the septum (the tissue separating the left and right heart) towards 
the LV to reduce size and promote healing of the LV. 
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To simulate the patient physiology, LPN parameters were scaled by body size 
using correlations developed earlier in this chapter and then manually tuned to match 
clinical data (Figure 16).  Changes to the pre-op LPN parameters to match post-op 




Figure 16. The pre- and post-op catheterization data for a pediatric patient with left 
ventricular dysfunction.  The pulmonary band is visible near center of the post-op image.  
All pressures shown are in mmHg, and percentages are oxygen saturations. 
 
 After tuning of key LPN parameters (Table 7), both the pre- and post-op 
physiologies were simulated with average parameter error of ±2.81 and ±3.04 
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respectively (units and values in Table 8).  To simulate post-op physiology, PVR and 
SVR were first increased to match clinical data.  To simulate the pulmonary band, the 
two pulmonary valve resistances, RPUL and KPUL, were increased until approximating the 
correct pressure difference across the pulmonary valve as measured in the clinical data.  
Notably, RV EMAX was fairly maintained (increasing by only 1%), but LV increased by 
90% from pre-op values.  This evidence provides initial support that the pulmonary band 
promoted LV recovery and increased contractility.  Future study will be needed to 
validate these findings over a larger population.  Little LPN refinement was needed to 
approximate the pediatric physiology, however adjustments are recommended for 
pediatric cohort studies. 
 
Table 7. LPN cardiac parameters for pre- and post-op simulations 
Parameter Pre-op Post-op 
RV EMAX (mmHg mL-1) 4.9 4.95 
LV EMAX (mmHg mL-1) 3.185 6.05 
LV EMAX/RV EMAX 0.65 1.22 
EOFFSET (mmHg mL-1) 1 1 
VRV0 (mL) -5 -5 
VLV0 (mL) 0 0 
RPUL (mmHg s mL-1) 0.005 0.05 




Table 8. Comparison of LPN and catheter data for pre- and post-op physiology 
a) Pre-op 
Parameter LPN Catheter Difference 
CO (L min-1) 0.76 0.80 -0.04 
Min PRA (mmHg) 2.28 6 -3.72 
Max PRA (mmHg) 10 7 3.00 
Min PRV (mmHg) 5.76 5 0.76 
Max PRV (mmHg) 38.33 40 -1.67 
Min PPA (mmHg) 20.02 17 3.02 
Max PPA (mmHg) 38.26 40 -1.74 
Min PLV (mmHg) 19.39 15 4.39 
Max PLV (mmHg) 83.37 85 -1.63 
MAP (mmHg) 61.03 62 -0.97 
LVESV (mL) 19.71 25 -5.29 
LVEDV (mL) 25.86 33.4 -7.54 
PVR (mmHg min L-1) 13.75 13.75 0 
SVR (mmHg min L-1) 71.29 72.5 -1.21 
    
b) Post-op 
Parameter LPN Catheter Difference 
CO (L min-1) 0.84 0.82 0.02 
Min PRA (mmHg) 6.77 12 -5.23 
Max PRA (mmHg) 14.55 15 -0.45 
Min PRV (mmHg) 9.21 12 -2.79 
Max PRV (mmHg) 62.07 62 0.07 
Min PPA (mmHg) 15.98 18 -2.02 
Max PPA (mmHg) 43.68 40 3.68 
Min PLV (mmHg) 14.21 24 -9.79 
Max PLV (mmHg) 102.6 108 -5.40 
MAP (mmHg) 75.78 75 0.78 
LVESV (mL) 14.25 12.8 1.45 
LVEDV (mL) 21.05 25.9 -4.85 
PVR (mmHg min L-1) 14.58 14.64 -0.06 
SVR (mmHg min L-1) 76.74 77.15 -0.41 
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Discussion 
 This chapter demonstrated the development of a LPN to simulate resting and 
exercise physiology in normal bi-ventricular adults.  New correlations with exercise level 
for key cardiovascular and cardiac parameters were developed to simulate exercise 
physiology.  These data were extracted from several similar studies and all correlations 
showed good fit (R2 > 0.85) for the models.  The LPN was initially tuned for a resting 
physiology and matched prior literature data within ±2.00 tolerance for most parameters.  
The exercise physiologies produced by the LPN also matched reference data for CO and 
MAP within ±10% for two different sized patients at multiple exercise levels.  The 
deviations between LPN and reference data increased for high fitness physiologies, but 
error for CO remained comparable to the low fitness simulations and results qualitatively 
agree with clinical observation.  Adjustments were also introduced for age related 
physiology changes, and the LPN produced trends qualitatively consistent with literature 
findings.  Therefore, this LPN has successfully demonstrated nascent capability of 
simulating a variety of bi-ventricular physiologies. 
 A clinical case study of a pediatric patient with left ventricular dysfunction was 
also explored.  The LPN parameters were scaled using correlations developed in this 
chapter and tuned to match pre- and post-op clinical data.  The LPN reproduced clinical 
data well and provides initial data regarding the physiological effect of a pulmonary 
band.  Overall, this demonstrates the capability of the bi-ventricular LPN of simulating 
patient physiology and as a tool for predicting surgical outcomes. 
Limitations and Future Work 
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 This chapter exclusively uses data from prior literature to create the correlations 
needed to calculate LPN parameters.  Despite this, patient fitness was explicitly 
accounted for by developing separate correlations, and age was controlled for the first set 
of correlations by using studies primarily investigating patients in their twenties.  
Nonetheless, a complete clinical study should recruit a patient cohort (and control group 
if necessary) to accurately model the specific patients under study.  These correlations are 
purposefully general to serve as an outline for simulating exercise physiology in a bi-
ventricular circulation.  Therefore, these correlations should be used with caution in 
future work. 
 The high fitness exercise physiology simulations did not match reference data as 
well as low fitness simulations.  Although separate correlations were developed for high 
fitness physiology when possible, there may be nuances not captured in this brief 
investigation.  Therefore, further refinement is needed to model high fitness physiology 
with better accuracy.  Clinical studies also occasionally report a category for “physically 
active” or “middle fitness” patients to fill the gap between low and high fitness levels.  
Insufficient literature data existed to develop all necessary correlations for a middle 
fitness level in this investigation, however this may be of interest to researchers wanting 
to account for more specific ranges of patient fitness levels. 
 Less literature exists to support the development of age related correlations with 
respect to exercise.  This is likely due to difficulty of assembling a cohort of varied age 
patients for which most cardiac parameters are well controlled and increased exercise 
intolerance with age.  It was also assumed that literature data skewed towards low fitness 
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levels for older age patients when patient fitness was not specified.  Nonetheless, 
refinement of age related correlations would be valuable for predicting long-term patient 
outcomes. 
 Lastly, sex specific differences can be introduced to the correlations.  It has been 
assumed that sex differences in physiology can be at least partially attributed to body 
size.  However, other factors affecting physiology may be present. 
 Future studies can further these early developments through several means.  First, 
a comprehensive repository of clinical reference data accounting for patient size, sex, 
age, and fitness level at various exercise levels should be compiled.  The correlations 
developed in this chapter can be refined with this additional data.  Second, a patient 
cohort can be recruited to test the LPN against new clinical reference data not used for 
development of correlations or models.  This serves as model validation.  Third, the LPN 
can be modified for a specific patient physiology, such as LV dysfunction, by adjusting 
appropriate parameters or models.  The LPN could then be used as a platform for 







In summary, the results presented in this thesis predict VAD treatment outcomes 
for stage 1 single ventricle patients by comparing performance between the pulsatile flow 
Berlin Heart EXCOR VAD and continuous flow HeartWare VAD.  An improved model 
for ventricular suction resistance was developed using experimental data from prior 
literature.  It was shown that the continuous flow VAD produced greater CO by at least 1 
L min-1 (p=0.0009) for all patients.  The CO produced by the 50 mL Berlin Heart was as 
much as 1.4 L min-1 (37.3%) below ideal due to incomplete filling caused by ventricular 
suction and shorter diastolic time at high HRs.  Manipulating VAD peak pressure and 
DFR settings from clinical recommendations increased CO by at most 0.07 L min-1 for 
any patient and failed to produce a statistically significant (p<0.05) improvement.  The 
Berlin Heart’s ability to produce CO ultimately remained filling limited.  Further work is 
needed to validate these findings over a broader population.  This study elucidates 
underlying mechanisms affecting outcomes of pulsatile and continuous flow VAD 
support in single ventricle patients and quantifies the impacts of ventricular suction, 
ventricular collapse, and incomplete filling on VAD supported physiologies. 
 A new LPN was also constructed to simulate adult bi-ventricular physiology.  
Correlations with exercise level were developed from prior literature data to calculate 
LPN parameters and all exhibited good fit (R2 > 0.85).  The LPN produced a resting 
physiology within tolerance of literature data for most parameters.  The LPN also 
 60 
produced exercise physiologies for two example patients within 10% of literature data for 
CO and MAP at multiple exercise levels.  Simulations of modified patient fitness level 
and age produced qualitative changes corroborating clinical evidence.  The LPN and 
correlations require refinement for greater detail and accuracy, however they remain a 














LPN Governing Equations 
 
For a LPN, there were two fundamental equations used to calculate the pressure 





                                                           (A1) 





                                                           (A2) 
Pressure and flowrate were related by the resistance as 
∆𝑃 = 𝑄𝑅     (A3) 
Atrial and ventricular contraction was represented by an active passive model.  
With this model, the pressure can be calculated based on volume and the time in the 
cardiac period.  Two components were present:  a passive curve and an active curve for 
contraction.  The passive pressure-volume equation for positive pressures is 
𝑃D7, = 𝑐 𝑒6 /W/~ − 1       (A4) 
where c and d are patient specific parameters and Vo is the reference volume.  The 
passive pressure-volume equation for negative pressures is 
𝑃D7,z = 𝑆z ln
/
/~
             (A5) 




          (A6) 
where C is another patient specific parameter. 
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An activation function describes the period of active contraction for the heart 
tissue (Figure A1).  When contraction occurs, AA(t) takes on a value between zero and 
one.  This is multiplied by Pactive and adds to the passive pressure.  In cases for which 
atrial pressure was negative, the activation function was set to zero.  This was to prevent 
adding a negative pressure predicted by Eq. (A6) for atrial volumes less than V0.  The 
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  𝑒𝑙𝑠𝑒
    (A7) 
where t1, ts, td, and tc are the time at end of contraction, total time for systole, total time 
for diastole, and total time for one cardiac cycle respectively. 
 
 
Figure A1. The activation function used to calculate the active pressure 
 
The equation for calculating the overall pressure is 
𝑃 𝑉, 𝑡 =
𝑃8D7𝐴𝐴 𝑡 + 𝑃D7,	  	  	  	  	  𝑉 ≥ 0
𝑃D7,z	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑉 < 0
        (A8) 
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The pressure drop through the systemic-to-pulmonary shunt was calculated with a 
model by Migliavacca et al. (44) and is 
∆𝑃Ql = 𝑅Ql𝑄Ql + 𝐾Ql𝑄Ql4                                  (A9) 
where RSH and KSH were patient specific parameters.  Similarly, flow through the heart 








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑒𝑙𝑠𝑒          (A10) 
for the atrial-ventricular valve, where KAV is a patient specific parameter, and 
𝑄>O =
0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑃Q/ < 𝑃>O
Z¨©ª
x KJ§\ª 0}[W0\ª WZ¨©ª
4§\ª
	  	  	  	  	  	  	  𝑃Q/ ≥ 𝑃Q/
                    (A11) 
for the aortic valve where RMYO, KAO are patient specific parameters. 
 For the pulsatile flow VAD model to represent a physical system, domain limits 
on volume were imposed.  The volume must remain between zero and the VAD size 
inclusive.  The volume of blood in the VAD was calculated at each iteration as the 







                                       (A12) 
The time derivative of volume is volumetric flowrate, so a more convenient form is 
6/[\]
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= 𝑄/>X,d® − 𝑄/>X,Ohk                                       (A13) 
Since flow in the VAD cannulas may become turbulent due to high flowrates 
through a small ID cannula, the Darcy-Weisbach equation is used to model the pressure 




𝑄4                (A14) 
where ΔP is the pressure drop, 𝑙 is the pipe length, fD is the dimensionless Darcy friction 
factor, ρ is the fluid density, and D is the pipe diameter.  Equation (A14) can be directly 
applied to the VAD cannulas since size dimensions and fluid properties are known.  The 
friction factor is a function of relative roughness, which is the quotient of absolute 
roughness to pipe diameter, and the Reynolds number.  The absolute roughness for the 
HeartWare inflow cannula was identified from literature (89).  The absolute roughness 
for the HeartWare outflow cannula and both Berlin Heart cannulas was assumed a 
conservative value representative of plastic tubing since no literature was available. 
For Eq. (A14) to be valid, flow in the cannulas must be incompressible and fully 
developed.  Blood is typically considered incompressible at physiological pressures.  
Fully developed fluid flow for turbulent Reynolds numbers can occur by 10 diameters of 
pipe length (90), which occurs for the length majority for three cannulas tested in this 
study.  The exception is the HeartWare VAD inflow cannula, which has an inner 
diameter of 10 mm and length of 35 mm.  However, since the cannula length is only 35 
mm, the pressure drop is considered negligible. 
The friction factor, fD, for the VAD cannulas was calculated using two different 




             (A15) 
and for turbulent flow (Re > 2300), the Haaland equation was used 







            (A16) 
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where ε is the absolute roughness of the cannula material.  The units of ε and D must 
match to form a dimensionless ratio. 
 A separate term for the dynamic pressure loss was also included for the inflow 
and outflow cannulas.  This is calculated by 
∆𝑃 = 0.5𝑘𝜌𝑉4       (A17) 
where kL is a minor loss factor dependent on geometry and is reported in introductory 
fluid mechanics textbooks.  In practice, it was found that this pressure loss was usually 5 
mmHg or less.  For example, a kL of unity with a flowrate of 5 L min-1 and 12 mm ID 
cannula would result in a pressure loss of approximately 2.2 mmHg. 
The intrathoracic pressure, Pith, was included in the bi-ventricular LPN model.  
The model (Figure A2) is similar to the activation function except the intrathoracic 
pressure has a period equal to four cardiac periods (one respiration period).  The model 
for Pith is given by 
𝑃D8 = 𝐴𝑃D8𝐴𝑅 + 𝑃D8,8     (A18) 
where AR is 
𝐴𝑅 = 0.5 1 − cos 4*8³´
J8µ
      (A19) 
and Pith,offset is the offset calculated by Eq. (27). 
 
 
Figure A2. The model for intrathoracic pressure adapted from a parent study (34) 
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An elastance model was used to calculate left and right ventricular pressures in 
the bi-ventricular LPN.  The normalized elastance function is 
𝐸𝑛 𝑡 = 𝐶+¶ cos 2𝜋𝑘𝑡 − 𝐶D¶ 2𝜋𝑘𝑡1v¶·^      (A20) 
where Crk and Cik are Fourier coefficients, which can be found in a parent study (34).  
The un-normalized elastance function can be expressed as 
𝐸 𝑡 = 𝐸P>𝐸𝑛
^.I
8¸¥
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       (A21) 
where E(t) is the elastance function and En is the normalized elastance function.  The 
ventricular pressure was then calculated by 
𝑉/ = 𝐸(𝑡)(𝑉/ − 𝑉 )           (A22) 
where V0 is the reference volume.  The elastance function was scaled by factor 0.4 for the 
right ventricle since it has lower contractility.  The scale factor was based on LPN tuning 




Suction Model Development and Testing 
 
The models from literature for ventricular resistance most suitable for use in the 
LPN were tested for validity in the pediatric patient circulation under study. 
The original concept of suction resistance is traceable to Schima et al. (53).  
Results from that study were later expressed mathematically by Choi (49) as 
𝑅QhN =
0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑃Q> > 𝑃kl
−3.5𝑃Q> + 3.5𝑃kl	  	  	  	  	  	  𝑃Q> ≤ 𝑃kl
                               (B1) 
where RSUC was the suction resistance, PSA was the atrial pressure, and PTH was the 
threshold pressure for suction to occur.  Values of -1 and 0 mmHg have been used for 
PTH by later studies (52, 55). 
 Two previous studies have presented models developed from least squares 
regression analysis of experimental data from animal experiments.  The development of 
these models was done retrospectively by finding the resistance that best recreated the 
experimental pressure and flowrate data based on the studied anatomy and physiology. 
The first of the two regression models was developed by Yu and Porter (55) and 
was 
𝑅QhN = 𝑘 + 𝑎D𝑃N>®DD·1,4,I, + 𝑏D𝑃Q/D4D·1 + 𝑐
6
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𝑃Q/                      (B2) 
where k was the constant resistance of the VAD cannula itself, PCAN was the pressure in 
the inflow cannula, PSV was the ventricular pressure, and a, b, and c were constants 
determined from the regression analysis.  Though not explicitly stated by the authors, 
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RSUC was assumed zero for any negative values since a negative resistance has no 
physical meaning. 





              (B3) 
where 𝜏Z}¬r was a time constant from the regression analysis.  𝑅QhN,¾ was modeled by 
𝑅QhN,¾ =
𝑘1 𝑒¶¥x /}[W/­¿ 	  	  	  	  	  	  	  	  𝑉Q/ < 𝑉kl
0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑉Q/ ≥ 𝑉kl
                            (B4) 
where ks1 and ks2 were constants determined from the regression analysis and VTH was the 
threshold volume for suction to occur.  A zero initial condition for RSUC was assumed.  
The threshold volume originally used by Lim et al. was arbitrarily chosen as the volume 
at which the left ventricular pressure was equal to 5 mmHg (personal communication).  
For consistency with the other suction models tested, the ventricular reference volume 
(for which PSV = 0 mmHg) was used instead as the threshold volume. 
Simulations with these models were done for each patient using the 50 mL Berlin 
Heart at 75 BPM and the HeartWare VAD at 3400 RPM since these settings would have 
the greatest tendency for ventricular suction to occur (Table B1). 
Each suction model produced similar results for pulsatile flow, but results varied 
for continuous flow.  For the continuous flow case, the models of Schima and Lim 
predicted pressure drops of approximately 50 mmHg at ventricular pressures close to -1 
mmHg.  This rapid suction response was unrealistic and these two models were not 
considered any further.  Conversely, the model by Yu and Porter predicted a pressure 
drop of only 3.14 mmHg for a ventricular pressure of -7.67 mmHg.  This slow suction 
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response was also unrealistic and this model was abandoned as well.  It was also expected 
that complete flow obstruction due to ventricular collapse could occur for the HeartWare 
VAD by 3400 RPM.  This was another reason for dismissing these three models.  As a 
caveat, these models were derived at least in part from animal experiments.  Therefore, 
they may be fairly accurate for circulations more similar to those of the original tests, but 
they did not appear well suited for pediatric human circulations. 
 Therefore, a new model is proposed to describe the ventricular suction resistance, 
RSUC, at negative ventricular pressures.  To make the model valid for any BSA, an 
allometric scaling law between RSUC and anatomical parameters was desired.  A 
parameter called the skweesh factor, Δ, is defined as 
∆= 𝐷Q/ + ℎQ/ − 𝑙            (B5) 
where DSV is the ventricular diameter, hSV is the ventricular wall thickness, and lh is the 
cannula head length.  If the skweesh factor equals zero, then the cannula head length 
equals the ventricular diameter and thickness.  In such a situation, the suction resistance 





     (B6) 
The scale factor of Δ with BSA was obtained by using Eq. (B6) for several BSA values 
with corresponding ventricular diameter and thickness (61) and cannula specifications 
from Berlin Heart.  Δ scaled with BSA0.3492, and so RSUC scaled with BSA-0.3492. 
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 The experimental data during suction events from several studies (48, 51, 53) was 




Figure B1. Experimental suction resistance data obtained from prior studies and 
normalized by BSA 
 
A trendline equation (R2 = 0.72) was created for this data by fitting a least squares 
power curve.  This model was expressed as 
𝑅QhN =
0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑃Q/ > 𝑃kl
0.2623 0.97870r\s − 1 𝐵𝑆𝐴W^.IJv4	  	  	  	  	  	  	  	  	  	  𝑃Q/ ≤ 𝑃kl
              (B7) 
In addition to this, a method was developed to dynamically calculate the threshold 
pressure for VAD flow to resume after a complete flow obstruction.  This was derived 
from a force balance between the cannula and ventricular pressures.  In other words, once 
PCAN (mmHg)































a complete flow obstruction occurred, a sufficient positive pressure must build up in the 
ventricle to “pop off” the inflow cannula from the ventricular wall.  The force balance 
starts with 
𝐹Q/ = 𝐹N>®      (B8) 
which can be expressed in terms of pressure by 
𝑃kl𝐴Q/ = 𝑃N>®𝐴N>®             (B9) 
and then ventricular surface area and cannula inner area by 
𝑃kl 4𝜋𝑟Q/4 = 𝑃N>®
*
J
𝐷N>®4       (B10) 
The ventricular radius can be related to BSA by using clinical data (60) to obtain 
𝑟 = 22.403555
5
𝐵𝑆𝐴    (B11) 





          (B12) 
where DCAN is in mm.  Values for the threshold pressure after a complete flow obstruction 
event typically range from 1-7 mmHg.  For reference, a cannula pressure of -100 mmHg, 
cannula diameter of 12 mm, and BSA of 0.3 m2 produces a ventricular pressure threshold 
of 6.0 mmHg. 
Using the same suction model testing process, the new model was compared to 
existing models with respect to its ability to produce realistic physiology for the patients 
in this study.  The new model proposed in this study is named “Proposed” and produced 
realistic results for both test cases (Table B1).  Although the mean value for RSUC was 
43.6 mmHg s mL-1 for PSV of 0.45 mmHg, this is due to complete flow obstruction 
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occurring in three patients.  In these cases, RSUC was set arbitrarily to 100 mmHg s mL-1 
for numerical stability and VAD flow was set to zero until PSV reached PTH.  This new 
model requires further validation from experimentation in future work.  Obtaining 
clinical data in human circulations is difficult since ventricular suction is undesirable in 
the clinical setting, but this remains an important task to improve accuracy of 
computational simulation of VAD treatment. 
 
Table B1. Cohort mean results from tests of prior ventricular suction resistance models 
and the model proposed in this study 
 Pulsatile Flow Continuous Flow 
Parameter Schima Lim Yu, Porter Proposed Schima Lim Yu, Porter Proposed 
CO (L min-1) 2.23 2.23 2.33 2.23 2.77 2.93 3.77 2.08 
VSA (mL) 12.14 12.14 11.55 12.14 10.58 8.26 3.60 10.56 
VSV (mL) 11.10 11.10 10.16 11.10 3.75 3.41 1.88 14.97 
PSA (mmHg) 2.29 2.29 1.58 2.29 1.57 0.73 -4.33 2.03 
PSV (mmHg) 0.68 0.68 -0.20 0.68 -0.37 -1.34 -7.67 0.45 
PAO (mmHg) 76.42 76.42 80.76 76.42 96.08 102.29 132.51 88.57 
PPA (mmHg) 11.47 11.47 11.07 11.47 12.54 12.18 9.23 11.75 
PCAN (mmHg) -10.89 -10.9 -11.14 -10.89 -54.15 -47.49 -10.81 -57.21 






Stage 1 Clinical Measurements and LPN Validation 
 
 This appendix includes the original clinical measurements (Table C1) and 
absolute percent differences between clinical measurements and pre-VAD LPN results 
(Table C2).  A percent tolerance of ±10% was desired and achieved for most cases.  The 
larger differences for the pulmonary flows are attributable to turbulence when taking 
measurements. 
 
Table C1. Clinical measurements of all six patients for flowrate and pressure at various 
parts of the circulation.  QP/QS represents the ratio of pulmonary to systemic flow and is 
ideally equal to unity. 
Patient A B C D E F 
QUB (mL s-1) 5.6 10.0 11.2 11.0 8.0 8.3 
QLB (mL s-1) 5.7 5.0 5.7 4.0 3.0 6.0 
QLPV (mL s-1) 4.5 4.0 2.7 6.5 9.0 8.1 
QRPV (mL s-1) 5.2 8.0 4.8 5.5 11.0 8.5 
CO (mL s-1) 21.0 27.0 24.4 27.0 31.0 29.8 
PSA (mmHg) 6.0 7.0 5.0 5.4 4.0 6.0 
PAO (mmHg) 52.0 53.0 43.0 53.0 72.0 51.0 
PPA  (mmHg) 12.0 15.5 13.0 12.7 13.5 11.0 





Table C2. The absolute percent differences between clinical measurements and pre-VAD 
LPN results for each patient 
Patient A B C D E F 
QUB 2.3 7.2 4.1 1.3 0.7 4.7 
QLB 1.2 1.4 2.6 2.0 1.0 1.5 
QLPV 4.9 19.8 1.5 2.0 4.8 1.4 
QRPV 8.8 17.3 1.7 4.9 0.2 12.5 
CO 1.9 4.4 2.9 1.5 0.5 2.0 
PSA 12.0 0.1 30.6 18.5 4.8 6.0 
PAO 0.3 2.2 1.9 0.2 0.3 0.2 
PPA 2.5 2.1 11.6 9.8 1.7 2.8 






Optimal Stage 1 Patient Specific Outcomes 
 
This appendix includes patient specific outcomes for pre-VAD heart failure (no 
ventricular contractility) (Table D1) and optimal VAD treatment (Table D2). The settings 
used to obtain data in Table D2 were reported in the results section (Table 2). 
 
Table D1. The patient specific data for zero ventricular contractility and no VAD 
Patient A B C D E F 
CO (L min-1) 0.2 0.12 0.04 0.21 0.45 0.16 
VSA (mL) 10.11 20.17 11.13 22.84 37.61 21.99 
VSV (mL) 37.29 41.01 22.82 48.71 49.59 34.15 
PSA (mmHg) 9.77 13.55 15.52 12.31 6.71 10.27 
PSV (mmHg) 13.83 15.4 16.29 15.95 15.45 12.08 
PAO (mmHg) 13.68 15.3 16.26 15.78 15.14 11.95 
PPA (mmHg) 11.26 14.54 15.96 13.8 9.66 10.93 









Table D2. Optimal patient specific outcomes for pulsatile flow (highest of either clinical 
or modified VAD settings) and continuous flow VADs 
a) Pulsatile Flow 
Patient A B C D E F 
CO (L min-1) 1.94 2.37 2.14 2.26 2.21 2.86 
VSA (mL) 4.05 9.66 4.33 10.72 25.28 12.59 
VSV (mL) 4.29 4.00 6.45 3.95 8.84 7.02 
PSA (mmHg) 1.36 1.74 1.06 1.99 2.61 2.32 
PSV (mmHg) 0.09 0.10 0.00 0.06 0.52 0.02 
PAO (mmHg) 80.83 82.03 60.67 76.74 89.39 87.25 
PPA (mmHg) 9.68 12.56 11.40 11.59 13.34 9.08 
QP/QS 0.73 0.61 0.37 0.68 1.61 0.80 
RSUC (mmHg s mL-1) 0.10 0.16 0.06 0.16 0.05 0.16 
VMIN (mL) 0.00 0.00 0.00 0.00 0.00 0.00 
VMAX (mL) 24.76 39.92 25.00 43.70 25.00 48.14 
 
b) Continuous Flow 
Patient A B C D E F 
CO (L min-1) 3.11 3.37 3.36 3.51 3.31 4.09 
VSA (mL) 0.85 1.09 0.81 1.15 14.99 6.04 
VSV (mL) 1.53 1.79 1.46 1.89 3.03 4.08 
PSA (mmHg) -4.75 -1.40 -6.12 -1.54 0.17 0.67 
PSV (mmHg) -6.94 -4.46 -8.33 -4.57 -1.97 -3.63 
PAO (mmHg) 134.20 118.90 92.30 117.30 143.53 128.82 
PPA (mmHg) 6.85 12.48 8.02 11.41 15.48 9.50 
QP/QS 0.57 0.53 0.31 0.53 1.33 0.69 






Exercise Level and MET 
 
This appendix includes selected examples of various exercises and the 
corresponding MET (65).  Discretizations of MET by intensity are also included for 
males and females. 
 
Table E1. Exercises and approximate MET for a 70 kg human 
Task (Male) MET 
Walking, 3 kph 1.8 
Walking, 5 kph 3.2 
Walking, 7 kph 5.3 
Running, 13 kph 12.9 
Running, 15 kph 14.6 





Very Heavy 8.0-9.9 






Very Heavy 6.0-7.5 





Bi-ventricular LPN Validation and Exercise Reference Data 
 
 This appendix includes the reference physiology data used from literature used to 
tune the bi-ventricular LPN for resting (Table F1) and exercise conditions (Table F2).  
The complete table of exercise physiology data adapted from literature is in Table F3.  A 
tolerance of ±2.00 for each parameter in units of Table F1 was desired for tuning of the 
resting LPN physiology and was achieved for most cases.  The larger differences 
occurred for the minimum cardiac pressures, which was due to Pith, and the ventricular 
volume indices, although mean volumes were approximately correct. 
 
Table F1.  The LPN results versus reference physiology for an example patient at rest 
Parameter LPN Reference Value Difference 
CI (L min-1 m-2) 3.21 3.30 (68, 92) -0.09 
QCOR/CO 0.04 0.04 (93) 0.00 
Min PRA (mmHg) -0.90 2 (94, 95) -2.90 
Max PRA (mmHg) 9.00 6 (94, 95) -3.00 
Min PRV (mmHg) -2.07 4 (94, 95) -6.07 
Max PRV (mmHg) 25.26 25 (94, 95) 0.26 
Min PCW (mmHg) 7.26 6 (95) 1.26 
Max PCW (mmHg) 11.91 12 (95) -0.09 
Min PLA (mmHg) -1.33 4 (94, 95) -5.33 
Max PLA (mmHg) 11.84 12 (94, 95) -0.16 
Min PLV (mmHg) -1.65 0 (96) -1.65 
Max PLV (mmHg) 127.00 125 (96) 2.00 
MAP (mmHg) 93.74 92 (94, 95)  1.74 
RVEDVI (mL m-2) 83.03 79 (97) 4.03 
RVESVI (mL m-2) 35.54 40 (97) -4.46 
LVEDVI (mL m-2) 68.98 62 (97–99) 6.98 
LVESVI (mL m-2) 17.59 24 (97–99) -6.41 
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Table F2. The reference data (68–70) used for tuning of cardiac exercise correlations for 
young (twenties and early thirties), healthy adults 
a) Low Fitness 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.50 95.05 9.25 1.65 
8 0.75 105.06 12.00 1.89 
12 0.99 115.07 24.28 1.88 
     
b) High Fitness 
MET CO/M0.75 (L min-1 kg-0.75) MAP (mmHg) PCW (mmHg) SV/M (mL kg-1) 
4 0.45 97.10 8.46 1.64 
8 0.71 101.68 7.42 1.89 




Table F3. The table of cohort mean exercise physiology data of young bi-ventricular 
adults at low and high fitness levels adapted from previous literature (68–70).  A blank 
entry indicates the parameter was not reported in the study. 
a) Low Fitness 












1.63 0.0057 206.3 0.27 91.5  1.34 
4.20 0.0147 286.1 0.47 92.3  1.64 
7.00 0.0245 392.7 0.66 99.0  1.67 
10.42 0.0365 514.0 0.80 111.8  1.56 
12.90 0.0451 576.4 0.94 115.6  1.63 
 
Gledhill 
3.51 0.0123 259.6 0.45 98.3  1.73 
6.85 0.0240 346.1 0.63 100.3  1.82 
8.96 0.0314 403.8 0.74 106.7  1.81 
10.73 0.0376 461.5 0.84 112.0  1.81 
13.01 0.0455 519.2 0.92 117.3  1.81 
14.70 0.0514 548.0 1.02 125.7  1.84 
       
Strickland 
1.29 0.0045  0.27  7.6 1.28 
5.00 0.0175  0.65  10.2 1.94 
8.14 0.0285  0.87  12.4 2.04 
9.43 0.0330  1.02  13.5 2.02 
10.57 0.0370  1.10  17.1 2.08 
11.71 0.0410  1.26  22.8 2.27 
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b) High Fitness 












1.47 0.0051 188.0 0.24 91.7  1.28 
4.03 0.0141 236.7 0.39 96.9  1.66 
6.49 0.0227 341.6 0.58 106.7  1.70 
9.78 0.0342 447.5 0.74 132.7  1.66 
12.66 0.0443 515.5 0.91 129.6  1.78 
14.50 0.0507 546.9 1.02 130.0  1.86 
       
Gledhill 
3.86 0.0135 255.0 0.53 83.0  2.07 
8.52 0.0298 339.9 0.80 84.3  2.36 
11.76 0.0411 396.6 1.02 91.7  2.56 
14.86 0.0520 453.3 1.21 98.0  2.66 
17.97 0.0629 509.9 1.39 103.3  2.72 
21.30 0.0745 538.2 1.53 108.0  2.87 
       
Strickland 
1.43 0.0050  0.27  7.0 1.28 
6.29 0.0220  0.65  8.0 1.94 
9.29 0.0325  0.87  7.6 2.04 
13.00 0.0455  1.02  10.0 2.02 
14.57 0.0510  1.10  12.6 2.08 






Simulation Flow Charts 
 
 This appendix includes flow charts of the simulation process for LPN tuning 
(Figure G1), single ventricle VAD supported circulation (Figure G2) and the normal bi-
ventricular circulation (Figure G3).  A flow chart demonstrating the iterative process to 
calculate vascular resistance during exercise for the bi-ventricular model is in Figure G4. 
 
 
Figure G1. Flow chart for LPN tuning  
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